EPZM News and Press, Epizyme Inc. From 11/06/20

Epizyme (EPZM): Q3 GAAP EPS of -$0.55 beats by $0.06.Revenue of $3.57M (-37.6% Y/Y) misses by $2.32M.Press Release For further details see: Epizyme EPS beats by $0.06, misses on revenue

Company Reports 55% Growth in Net Revenue of TAZVERIK ® Compared with 2Q 2020 Expansion of Loan Facility with Pharmakon Advisors; $150 Million Drawn Down to Fund Important Growth Initiatives and Extend Operating Runway into At Least 2023 On-Track to Initiate E...

Additional Capital Expected to Extend Company’s Operating Runway into At Least 2023 Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the company has ...

Epizyme (NASDAQ:EPZM) is scheduled to announce Q3 earnings results on Friday, November 6th, before market open.The consensus EPS Estimate is -$0.60 (-50.0% Y/Y) and the consensus Revenue Estimate is $5.89M (+3.0% Y/Y).Over the last 1 year, EPZM has beaten EPS estimates 100% of the time and ha...

[[AES]], [[AMRX]], [[COTY]], [[CQP]], [[CVS]], [[CWT]], [[DISH]], [[DOC]], [[ELAN]], [[ENB]], [[EPZM]], [[ESNT]], [[GCP]], [[GOLF]], [[HMSY]], [[HRC]], [[HSY]], [[LNG]], [[MAR]], [[MBUU]], [[MD]], [[MGA]], [[MOG.A]], [[MYL]], [[PRIM]], [[SABR]], [[SSP]], [[TILE]], [[TU]], [[UFS]], [[VIAC]], [...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its third quarter 2020 financial results and other busine...

Data Supported Accelerated Approvals of TAZVERIK for the Treatment of Both Epithelioid Sarcoma and Relapsed/Refractory Follicular Lymphoma Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic ...

Epizyme, Inc . (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Morgan Stanley 18th ...

Image source: The Motley Fool. Epizyme Inc   (NASDAQ: EPZM) Q2 2020 Earnings Call Aug 4, 2020 , 8:30 a.m. ET Operator Continue reading

Epizyme, Inc. (EPZM) Q2 2020 Earnings Conference Call August 4, 2020, 8:30 am ET Company Participants Alicia Davis - IR, THRUST Strategic Communications Rob Bazemore - President & CEO Matt Ros - Chief Strategy & Business Officer Paolo Tombesi - CFO Shefali Agarwal - C...